I am delighted to open this edition with the exciting announcement that European Endocrinology is now officially indexed on PubMed Central. As a team we are very excited that our content will be included in this very well-respected database, and excited to share our articles with more doctors and researchers. We would like to take this opportunity to thank all of our Editorial Board and authors for their collaboration over the past few years and welcome colleagues in the endocrinology field to submit their work to our upcoming editions. Instructions for authors and submission guidelines are available at www.touchENDOCRINOLOGY.com.
Turning to this edition of European Endocrinology, the increasingly important subject of diabetes forms the main focus of the articles in this issue. We begin with a review from Priya and Kalra that considers the impact of mindfulness meditation on patients with diabetes. The psychological impact of diabetes is also explored in an original study by Kalra et al evaluating the GlucoCoper, which was found to be an effective means of assessing coping mechanisms in people with diabetes distress.
Blood glucose monitoring is an essential part of the lives of all people living with diabetes. Adolfsson et al. review the advantages and limitations of real-time continuous glucose monitoring (CGM) and intermittently scanned CGM. In addition, Hautier-Suply et al. describe a retrospective review of the patient data automatically uploaded to the Cellnovo Online platform, which forms part of the Cellnovo Diabetes Management System. Finally, Omengue et al. present the findings of a fascinating study showing that hydroquinones in body lotions can cause significant variations in capillary blood glucose measurements.
The effective management of diabetes using insulin relies on a safe, convenient and cost-effective delivery system; Singh et al. present a study comparing insulin pen devices and disposable plastic syringes.
One of the hottest topics in type 2 diabetes is the cardiovascular outcomes trials of glucose-lowering drugs. The endocrine community is eager to discover whether the findings of the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) study and Canagliflozin Cardiovascular Assessment Study (CANVAS-PROGRAM) study also apply to dapagliflozin and prove a class effect for sodium-glucose cotransporter 2 (SGLT2) inhibitors. Gallwitz reviews real-word data on the SGLT2 inhibitors.
